Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. (SLDB) files reports and disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed issuer. These SEC filings provide detailed information on the company’s clinical programs, financial condition, risk factors and material corporate events related to its development of precision genetic medicines for rare neuromuscular and cardiac diseases.
Among the documents available, Form 10-K annual reports and Form 10-Q quarterly reports typically discuss Solid Biosciences’ gene therapy pipeline, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia and SGT-601 for TNNT2-mediated dilated cardiomyopathy, along with its AAV-SLB101 capsid platform and broader development activities. These filings outline the company’s business description, research and development focus and key risks.
Form 8-K current reports, such as the filing describing interim data from the INSPIRE DUCHENNE Phase 1/2 trial of SGT-003, provide updates on material events, including clinical data readouts, regulatory developments, corporate presentations and other significant announcements. Investors can also review information on equity awards and stock plans, as referenced in company communications about inducement grants made under Nasdaq Listing Rule 5635(c)(4).
This SEC filings page offers real-time access to Solid Biosciences’ submissions from the EDGAR system, along with AI-powered summaries that highlight key points from lengthy documents. Users can quickly identify disclosures on clinical trial progress, gene therapy strategy, regulatory interactions and other factors that may be important when evaluating SLDB.
RA Capital Management and affiliated funds report beneficial ownership of 9,663,926 shares of Solid Biosciences common stock, representing 9.9% of the class. The position is held through RA Capital Healthcare Fund, the RA Capital Nexus Fund, a managed account and pre-funded warrants.
In February 2026, the healthcare fund bought 354,936 shares in open-market trades at a weighted average price of $6.49 per share for total consideration of $2,304,350.99. On March 6, 2026, it also acquired 4,456,327 pre-funded warrants in a private placement for $24,995,538, each exercisable at $0.001 per share but capped by a 9.99% beneficial ownership blocker.
The March 2026 private placement issued 14,973,257 new shares and 27,807,482 additional pre-funded warrants to institutional investors. Solid Biosciences agreed in a registration rights agreement to register for resale the new shares and the common stock underlying the March 2026 pre-funded warrants.
Solid Biosciences Inc. entered into a private placement with institutional investors to sell 14,973,257 common shares at $5.61 per share and pre-funded warrants for 27,807,482 shares at $5.609 per warrant, for expected gross proceeds of about $240.0 million and net proceeds of about $226.8 million.
The company expects to report preliminary cash, cash equivalents and available-for-sale securities of roughly $187.9 million as of December 31, 2025, and believes its cash plus net placement proceeds can fund operations into the first half of 2028. Pre-funded warrants are immediately exercisable at $0.001 per share and are subject to beneficial ownership limits of 4.99% or 9.99%, up to a maximum of 19.99%. The company agreed to register the resale of all securities issued and to pay liquidated damages of 1.0% of each investor’s amount per 30-day period if specified registration deadlines are not met.
Solid Biosciences Inc. President and CEO Alexander Cumbo reported a combination of RSU vesting and a related tax sale. On February 13, 2026, he acquired 30,031 shares of common stock at $0.00 per share through the conversion of restricted stock units, increasing his directly held common stock.
On February 18, 2026, he sold 16,644 shares of common stock in an open‑market transaction at a weighted average price of $5.8233 per share to cover withholding taxes following the RSU vesting, under a pre‑existing automatic sales instruction that is not a discretionary trade. After these transactions, he directly owned 235,405 shares of common stock and 60,063 RSUs that vest over four years from the February 13, 2024 grant date.
Solid Biosciences filed a Form 144 reporting a proposed sale of Common Stock tied to the settlement of vested restricted stock units on 02/18/2026. The filing lists proposed/settled share movements including examples of prior sales by a selling holder, including Brooks Gabriel: 28,335 shares and 12,616 shares.
The notice ties the 02/18/2026 entry to compensation (RSU settlement); proceeds and specific distribution methods are shown for prior sales in the excerpt.
Cumbo Alexander filed a Form 144 reporting proposed sales of Common Stock. The notice lists three transactions: 12/03/2025 sale of 10,808 shares for $55,228.88, 02/02/2026 sale of 80,258 shares for $516,612.72, and 02/04/2026 sale of 48,913 shares for $315,079.69.
The excerpt also shows the settlement of 16,644 vested restricted stock units on 02/18/2026 reported as issuer compensation.
Solid Biosciences Inc. Chief Regulatory Officer Jessie Hanrahan reported insider equity activity involving restricted stock units and related tax sales. On February 13, 2026, she acquired 8,125 shares of common stock through the exercise of restricted stock units at a price of $0.00 per share. On February 18, 2026, she sold 4,134 shares of common stock at a weighted average price of $5.8233 per share, with actual sale prices ranging from $5.23 to $6.14, to cover withholding taxes following RSU vesting under a pre-established automatic sell-to-cover instruction. After these transactions, she held 74,318 shares of common stock and 16,250 restricted stock units.
Harahan Jessie submitted a Form 144 to sell 4,134 shares of common stock related to the settlement of vested restricted stock units, with settlement dated 02/18/2026. The filing lists prior dispositions in the past three months of 4,483 shares on 12/03/2025, 26,535 shares on 02/02/2026, and 12,348 shares on 02/04/2026.
Solid Biosciences Inc. director Ilan Ganot reported a small net sale of shares mainly tied to restricted stock unit vesting and tax withholding.
An entity associated with his wife sold 2,658 shares of common stock in an open-market transaction at a weighted average price of $5.8233 per share, with individual trades ranging from $5.23 to $6.14. According to the disclosure, this sale was made to cover withholding taxes after previously granted restricted stock units vested and followed a durable automatic sales instruction adopted by Ms. Ganot, so it was not a discretionary trade.
On the same date, 4,861 restricted stock units held by Ms. Ganot converted into an equal number of common shares at no exercise price, reflecting the one-for-one RSU-to-share ratio. After these transactions, Mr. Ganot’s reported holdings include shares held individually, jointly with his spouse, and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences submitted a Form 144 reporting a proposed sale of 3,616 shares of common stock to settle vested restricted stock units on 02/18/2026.
The filing lists prior sales by the reporting person: 2,701 shares on 12/03/2025, 26,250 shares on 02/02/2026, and 10,905 shares on 02/04/2026. The securities are listed on NASDAQ.
Solid Biosciences (SLDB) reporting person submitted a Form 144 to sell Common Stock tied to the settlement of vested restricted stock units held indirectly through his spouse on 02/18/2026. The filing lists prior sales in 01/05/2026, 01/28/2026, and 02/04/2026 with share amounts and aggregate values included.